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Abstract
Background:  Infants usually respond differently to a neuromuscular relaxant compared to
children or adults. Isoflurane is commonly used as an anesthetic gas in infants. In an RCT design,
we investigated whether a dose of mivacurium 250 µg/kg results in faster onset of action than 200
µg/kg in infants under isoflurane anesthesia. Spontaneous recovery times and cardiovascular
response were also evaluated.
Methods: Twenty-four low surgical risk children, aged 6–24 months, undergoing an elective
surgery and requiring tracheal intubation were selected. After anesthetic induction, patients
randomly received an iv bolus dose of mivacurium 200 or 250 µg/kg. After maximal relaxation, the
patient was intubated. Isoflurane was administered to maintain anesthetic level during the surgical
procedure. Neuromuscular function was monitored by accelerometry (TOF-Guard) at the
adductor pollicies. The first twitch (T) of the TOF and the T4/T1 were measured. The time-course
of heart rate and systolic and diastolic blood pressure were analysed by transforming them into
their respective areas under the curve.
Results: Mivacurium 250 µg/kg produced a maximal T block faster than 200 µg/kg, i.e. 2.4 ± 1.1 vs.
3.5 ± 1.4 min (p < 0.05). Spontaneous recovery times were similar in both groups. Heart rate was
similar between doses while systolic and diastolic blood pressures were lower with the higher dose
(p < 0.05). Flushing was observed in two cases, one in each group.
Conclusions: The maximal effect of mivacurium 250 µg/kg, in infants under isoflurane anesthesia,
was present one minute faster than 200 µg/kg. However, it produced a significant cardiovascular
response.
Background
Mivacurium is a short acting benzylisoquinoline non-de-
polarizing neuromuscular blocking agent, with a demon-
strated safety and efficacy both in children and adults [1–
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3]. It has been in clinical use for a long time and the clin-
ical pharmacology has been widely documented.
In children, administration of isoflurane previous to and
during the effect of vecuronium or mivacurium increases
their spontaneous recovery times in a time-dependent
manner [4,5]. However, these times are not modified if
the anesthetic gas is administered after the peak effect of
the neuromuscular relaxant is produced [6].
Furthermore, despite infants usually respond differently
to the effects of a neuromuscular relaxant from children
or adults do, and that isoflurane is commonly used in
children including infants, only few studies have evaluat-
ed the effect of mivacurium during isoflurane anesthesia
[4,7,8].
In the current study, we compared the effect of 200 and
250 µg/kg of mivacurium in infants during isoflurane
anesthesia in order to investigate whether the higher
dose resulted in a faster onset of action. Spontaneous re-
covery times and cardiovascular response to the neu-
romuscular relaxant were also compared.
Methods
The study was approved by the Institutional Investiga-
tion Committee of the Hospital Infantil de México Fred-
erico Gómez and informed written consent was obtained
from parents. The study design was a double blind rand-
omized controlled trial comparing 200 and 250 µg/kg of
mivacurium during isoflurane anesthesia. Patients aged
6 to 24 months, ASA I, were selected from those suffering
any ophthalmic, oto-rhynologic, plastic or orthopedic
disease and undergoing an elective surgery of a planned
duration not longer than 1 h while requiring tracheal in-
tubation during the procedure. Those patients undergo-
ing any procedure requiring important mobilization
potentially interfering with the neuromuscular monitor
during surgery or receiving any drug known or suspected
to interfere with neuromuscular transmission were not
included. Premedication was not used in any patient. Se-
lection and inclusion of patients was performed during a
period of three months. Sample size was computed ac-
cording to the following equation for estimating the sam-
ple size for the comparison of mean values of two
independent samples [9]:
where K= 10.5 based on tables of the standard normal
curve at an α  level of 0.05 and β  level of 0.10 for a two-
sided test, σ 2= 0.302 min is the expected variance ac-
cording to the standard deviation observed in 15 previ-
ous studies (range 0.06 to 1.26 min) administrating
mivacurium in children under different clinical condi-
tions, ∆ 2 = 12 min. Equation resulted in a sampling size
of 1.9 patients in each group, we therefore arbitrarily in-
creased the sample size to 12 subjects in each group that
could satisfy the minimum significant difference of 1 min
between two means associated to a standard deviation of
0.70 min.
One hundred and eighty-four patients were potentially
eligible. However, because of the requirements of equip-
ment, extra personnel and fasting period for patients,
only 101 patients undergoing surgery between 8 and 12
a.m. were assessed for eligibility and were enough to ob-
tain the required sample size. Fifty-five patients not
meeting inclusion criteria and parents of 22 patients re-
jected participation into the study before randomization.
After written consent was obtained, the selected 24 pa-
tients were randomized by means of a table of random
numbers for two equal groups of 12 patients previously
designed by a colleague without any participation in the
study. For clarity and according to the CONSORT state-
ment [10], a flow chart of the progress throughout the
phases of the current randomized trial was constructed
(Figure 1)
Procedures, previously used for other study [6], were as
the following: on arrival at the operating room, children
were cardiovascular monitored, i.e. ECG, pulse oxymetry
Figure 1
Flow chart of the progress of the study throughout the
phases of a randomized trial, i.e. enrollment, intervention
allocation, follow-up and data analysis.BMC Anesthesiology 2001, 1:1 http://www.biomedcentral.com/1471-2253/1/1
and non-invasive blood pressure by means of an auto-
matic device. Anesthesia was induced using atropine (20
µg/kg), fentanyl (2 µg/kg) and propofol (3 mg/kg). Nor-
mocapnia and normal body temperature were main-
tained intra-operatively. After induction of anesthesia,
children were ventilated with 100%-oxygen. Thereafter,
using surgical tape, the acceleration transducer of a TOF-
Guard neuromuscular transmission monitor (manufac-
tured by Biometer International A/S, Odense, Denmark)
was attached to the flexor aspect of the freely mobile
thumb. The two cutaneous electrodes to stimulate the ul-
nar nerve were fixed to the anterior forearm just proxi-
mal to the wrist joint. The TOF-Guard was programmed
to automatically deliver supramaximal train-of-four
stimuli to the ulnar nerve in two phases. During the first,
the stimuli were programmed to be delivered every 15 s
from baseline to 5 min. Thereafter, the stimuli were de-
livered every minute until complete recovery (T ≥  95%)
was observed, and the stimuli sequence was stopped by
the operator.
Mivacurium (commercialized in our country until 1999
by Glaxo-Wellcome de México, Mexico City, Mexico) was
administered as a bolus dose into the T-connector of a
rapidly running intravenous infusion. The TOF-Guard
was calibrated by using its automatic start-up procedure,
and the programmed sequence was started immediately
before mivacurium administration. The T (%) and (T4/
T1) of the TOF response were simultaneously measured.
Time consumed from induction of anesthesia until miva-
curium administration was 3 to 5 min.
Finally, intubation was attempted in all infants when ei-
ther T= 0% or T <25% with no changes during a one-
minute period together with the presence of clinical sat-
isfactory conditions for tracheal intubation were present.
Clinical condition was evaluated by other of the authors
also blinded for patient allocation group, by using the
scale described by Fahey et al. [11].
After intubation and throughout a period of time not
longer than 3 minutes, administration of isoflurane in
oxygen was initiated and slowly increased until a dose of
1.5–2.0 MAC end-tidal adjusted for age was reached. A
flow rate of 4 L/min of oxygen was administered through
a semiopen Bain circuit and an end-tidal carbon dioxide
tension was maintained between 32 and 38 mmHg. At
ages of patients studied herein, one unit of MAC of iso-
flurane is equivalent to 1.6% [12]. End-tidal concentra-
tion of isoflurane was kept stable until the endpoint of
neuromuscular monitoring had been attained (T ≥  95%)
in every patient. At the end of the surgical procedure, ad-
ministration of the anesthetic gas was slowly discontin-
ued, during a process of 5 to 10 minutes, until patient
presented clinical conditions to be extubated. Oxygen
administration was maintained until a complete clinical
recovery was observed and patient was able to self main-
tain the ventilatory function. No additional drug was re-
quired during the anesthetic procedure. Information was
recovered and captured in a printed data collection form.
This process was performed by one of the authors ignor-
ing the dose of mivacurium. Thereafter, data were trans-
ferred to an electronic form (Microsoft® Excel 97).
Computation of the onset and spontaneous recovery
times and statistical analysis were performed by a blind-
ed process.
Measurements and outcomes
For analysis of the effect, the neuromuscular response
was divided in two phases. Response from the baseline
until the maximal relaxation was observed and main-
tained was used to compute the times to a block of 90
(OA90) and 99.9% (OA100). Second, response starting
with the maximal relaxation until it returned to baseline
values was used to obtain the times to spontaneous re-
covery of 10, 25, 50, 75 and 90% of the neuromuscular
function. To obtain these parameters, both T and T4/T1
responses were analyzed.
The time-course of T or T4/T1 in each phase was consid-
ered sigmoidally related to time, and equation used to fit
them was the following [13]:
The model used is a logistic equation where E = the ob-
served response, t = the time at which every response
was registered, E0= response at zero time, b= slope fac-
tor, t50 = time at which half-maximal response is given,
and Emax = maximal response. In all patients the maxi-
mal block and maximal recovery were > 96%. Therefore
the Emax was obtained by transforming the maximal ef-
fect registered by the TOF-Guard into the 100%, a value
fixed into the model. All the other values of the effect
were then transformed according to the new 100%. Value
of the E0was then also fixed to the model. The complete
neuromuscular response was fitted to time by using the
SigmaPlot 4.01 (SPSS México, Mexico City, Mexico) for
Windows™ 95, and b and t50 were computed by itera-
tion. Thereafter, calculated effect was obtained by proper
arrangement of the equation described above. For each
patient, the HR and SBP and DBP were transformed into
the area under the heart rate-time curve (AUC-HR), and
into the area under systolic and diastolic blood pressure-
time curve (AUC-SBP and AUC-DBP, respectively). Each
AUC was obtained with data obtained immediately afterBMC Anesthesiology 2001, 1:1 http://www.biomedcentral.com/1471-2253/1/1
mivacurium was administered until 30 min. The AUC's
were computed by means of the Microsoft® Excel 97 us-
ing an adaptation of a standard procedure [14], as fol-
lows:
where Y represents HR, SBP or DBP, the X is the time at
which Y was measured, and 1,2...n are the progressive
values until the last observation was performed. By using
this equation, the overall response of HR, SBP and DBP
is obtained and compared between groups, avoiding the
time-by-time comparisons.
Finally, the onset of action was considered as the prima-
ry outcome of the study while spontaneous recovery
times and cardiovascular response as secondary out-
comes.
Statistical analysis
All data were presented as mean ± SD, ranges and when
indicated the 95% confidence intervals for the difference
for parametric data were computed. The Student t test
was used to compare age and weight between the two
groups of treatment, while the Fisher exact test was used
for comparison of gender. The quality of fit of the phar-
macodynamic (sigmoidal) model to the data was judged
by correlation coefficient of observed to predicted effect
automatically computed by SigmaPlot®. Visual exami-
nation of plots of the ratio of observed to predicted re-
sponse and plots of observed minus predicted response
in function of time was also performed, considering a
good agreement between observed and predicted re-
sponse when ratios approached 1 and differences ap-
proached 0.
The times to OA and to spontaneous recovery of neu-
romuscular function were also compared between
groups by the unpaired Student t test. The unpaired Stu-
dent t test was also used to compare each AUC, i.e. AUC-
HR, AUC-SBP and AUC-DBP, between groups.
Ancillary analyses
In every group, the HR and SBP and DBP data obtained
5 min after mivacurium was administered were com-
pared to their respective baseline values by means of the
paired Student t test. In order to evaluate the effect of age
and weight into onset and recovery times (data from all
children), a single linear regression analysis (y= mx+b)
was performed between each of the onset and recovery
times as the dependent or explained variable and age or
weight as the independent variable.
Finally, descriptive statistics, paired and unpaired Stu-
dent t test and linear regression analysis were performed
using the software WinSTAT (R. Fitch Software, Cam-
bridge, MA, USA) for Microsoft® Excel. A two-tailed
probability of p < 0.05 was considered significant in eve-
ry test or analysis.
Results
The two groups were similar in demographic data in-
cluding gender, age and weight (Table 1), reflecting a
successful randomized procedure. All patients reached
the maximal (100%) relaxation response and received a
Fahey scale 0 for tracheal intubation, and were extubat-
ed and discharged from the operating room with a full re-
covery of the neuromuscular function (T ≥  95%) and
without any complication of drug administration. All in-
fants completed the study and data were analyzed in the
group they were randomized (Figure 1).
Responses from all patients were successfully modeled.
This was proved by regression coefficients always greater
than 96%, by plots of ratio of observed to predicted re-
sponse in function of time approaching 1, and plots of ob-
served  minus predicted response in function of time
approaching 0. The times to OA and to spontaneous re-
covery of T and T4/T1 of the two groups were summa-
rized in Tables 2 and 3, respectively. In relation to T
response (Table 2), the maximal block with mivacurium
250 µg/kg appeared one minute faster than 200 µg/kg (p
< 0.05), whereas spontaneous recovery times were simi-
lar between groups. However, analyzing T4/T1 response,
similar times to OA and to spontaneous recovery were
obtained with both doses (Table 3). Additionally, no re-
lationship between age or weight and any of the OA or
spontaneous recovery times was demonstrated by linear
regression analysis.
In relation to the cardiovascular response, the AUC-HR
was similar in the two groups (p > 0.05) while both AUC-
SBP and AUC-DBP were significantly lower (p < 0.05) in
patients receiving 250 µg/kg. The HR at 5 min after any
dose of mivacurium was administered significantly in-
creased in relation to baseline values (p < 0.05), while a
similar time-course of the HR was observed with the two
doses of mivacurium (Figure 2). The time-course of both
SBP (Figure 3) and DBP (Figure 4) reflected the differ-
ences observed in their respective AUC's. Transient
flushing was observed in two cases: one female patient,
weighing 13 kg, aged 22 mo., and receiving mivacurium
200 µg/kg, and one male patient, weighing 8.3 kg, aged
8 mo., and receiving mivacurium 250 µg/kg.
Discussion
In this study patients underwent muscle relaxation with
mivacurium. Anesthesia was intravenously induced andBMC Anesthesiology 2001, 1:1 http://www.biomedcentral.com/1471-2253/1/1
maintained with isoflurane administered when relaxa-
tion had reached a maximal response. The same clinical
model was previously used to evaluate the effects of ro-
curonium [6], and clearly differs from other studies.
Mainly, intubation followed by gas administration was
performed after a maximum neuromuscular block was
present, avoiding any effect of the anesthetic gas on the
times to OA. However, isoflurane is able to increase twice
the spontaneous recovery of vecuronium in children, and
prolongs recovery times for more than 50% after 30 min
of its administration [4,5]. In the present study similar
spontaneous recovery was observed in the two groups,
and our results are comparable to 15–20 min for T90 of
Goudsouzian's review article [3]. Furthermore, our T25
values are longer than those obtained with 300 µg/kg of
mivacurium under nitrous oxide-halothane or nitrous
Table 1: Demographic data
DOSE (µg/kg) 95% CI for the
200 250 difference
Gender (M:F) 7:5 6:6 -
Age (month) 18.0 ± 6.3 (6.0 – 24.0) 15.2 ± 6.4 (8.0 – 24.0) - 2.4 to 8.0
Weight (kg) 11.1 ± 2.2 (7.0 – 15.0) 10.3 ± 2.3 (6.5 – 14.0) -1.1 to 2.7
mean ± SD (ranges)
Table 2: Times to OA and to spontaneous recovery of T
DOSE (µg/kg) 95% CI for the
200 250 difference
OA90 (min) 2.0 ± 0.6 (1.4 – 3.6) 1.6 ± 0.6 (1.1 – 2.9) -0.1 to 0.9
OA100 (min) 3.5 ± 1.4 (1.9 – 6.0) 2.4 ± 1.1* (1.1 – 4.7) 0.1 to 2.1
T10 (min) 10.1 ± 2.2 (5.4 – 13.1) 11.0 ± 1.9 (8.2 – 13.8) -2.6 to 0.8
T25 (min) 11.7 ± 2.5 (6.4 – 15.1) 12.5 ± 1.93 (9.5 – 15.9) -2.6 to 1.0
T50 (min) 13.5 ± 2.9 (7.6 – 17.4) 14.2 ± 2.1 (10.9 – 18.3) -2.8 to 1.4
T75 (min) 15.6 ± 3.6 (8.9 – 20.0) 16.2 ± 2.4 (12.6 – 21.1) -3.1 to 1.9
T90 (min) 18.0 ± 4.5 (10.5 – 23.9) 18.4 ± 3.0 (14.5 – 24.3) -3.6 to 2.8
mean ± SD (ranges) *p < 0.05
Table 3: Times to OA and to spontaneous recovery of T4/T1
DOSE (µg/kg) 95% CI for the
200 250 difference
OA90 (min) 1.9 ± 0.6 (1.4 – 3.6) 1.6 ± 0.5 (1.0 – 2.7) -0.2 to 0.8
OA100 (min) 2.3 ± 1.1 (1.4 – 5.2) 2.1 ± 1.0 (1.0 – 4.5) -0.7 to 1.1
T4/T110 (min) 10.3 ± 1.9 (5.3 – 12.8) 11.5 ± 2.1 (8.3 – 14.2) -2.9 to 0.5
T4/T125 (min) 11.9 ± 2.0 (6.8 – 14.8) 13.0 ± 2.0 (9.9 – 15.5) -2.8 to 0.6
T4/T150 (min) 13.9 ± 2.2 (8.6 – 17.1) 14.7 ± 1.9 (11.7 – 18.1) -2.5 to 0.9
T4/T175 (min) 16.1 ± 2.6 (10.9 – 19.9) 16.7 ± 2.0 (13.8 – 21.2) -2.5 to 1.3
T4/T190 (min) 18.8 ± 3.2 (13.8 – 23.1) 18.9 ± 2.5 (16.1 – 24.7) -2.5 to 2.3
mean ± SD (ranges)BMC Anesthesiology 2001, 1:1 http://www.biomedcentral.com/1471-2253/1/1
oxide-opioid anesthesia [15]. These considerations sug-
gest that isoflurane does affect the spontaneous recovery
similar to or higher than other anesthetic techniques.
The duration of action of some non-depolarizing neu-
romuscular blocking agents differs with age, even when
administered in equipotent doses [16]. Other studies
have also demonstrated age differences of response to
mivacurium [4,7,14,17,18]. In the current study, we ob-
tained no significant relationship between age or weight
and any of the OA or spontaneous recovery. The range of
6 to 24 months of our patients could be broad to study
the effect of age in 24 patients. However, a Canadian
group of pediatric anesthesiologists found similar neu-
romuscular effects of mivacurium in patients aged be-
tween 2 mo. to 10 yr. [19,20], supporting our results.
Additionally, extremely wide ranges of neuromuscular
response in children have been described for other neu-
romuscular blocking, e.g. T75 ranged from 27.3 to 91.4
min with rocuronium 800 µg/kg and T25–75 ranged from
6.0–22.8 min with rocuronium 600 µg/kg [6,21]. In re-
lation to mivacurium, cholinesterase activity level is a
major determinant of the spontaneous recovery of miva-
curium in pediatric population [8,22]. We did not quan-
tify enzyme levels and therefore the inter-individual
variations of spontaneous recovery times are difficult to
be interpreted. However, coefficient of variations of T re-
sponse to mivacurium varied from 14.8 to 45.8% and T75
response ranged from 8.9 to 20 min, representing a less
markedly variation than rocuronium. Furthermore, an
atypical response was not present in any patient. There-
fore, we considered that our patients were a population
without marked differences in plasmatic cholinesterase
activity.
In relation to cardiovascular response, administration of
mivacurium 200 to 300 µg/kg in infants and children
has demonstrated minor changes or lack of significant
changes in HR and blood pressure [14,18,19,23,24]. We
observed an increment in HR at the first minute, reach-
ing the top at 5 min in both groups. Agents having vary-
ing cardiovascular effects were administered in addition
to and preceding the mivacurium, when assessing the
cardiovascular response. Atropine administration and
combination of fentanyl and propofol could certainly
have an effect on heart rate and blood pressure in our pa-
tients. However, a drop in blood pressures indicated by
lower AUC-SBP and AUC-DBP of patients receiving mi-
vacurium 250 µg/kg was significant. The review article of
Goudsouzian states that reported ED95 of mivacurium
for infants ranges from 65–94 µg/kg [3]. The dose of 200
µg/kg will then be2 to 3 times the referenced ED95, and
250 will be 2.5 to approximately 4 times. We therefore
considered that these changes could be mainly related to
histamine release with both doses, probably more
marked with the highest dose. Fortunately, in most cases
the histamine release and cardiovascular changes have
lacked clinical significance [25].
Figure 2
The time course of HR after administration of mivacurium. *P
< 0.05, baseline vs. 5 min HR values of patients receiving
mivacurium 200 µg/kg; **P < 0.05, baseline vs. 5 min HR val-
ues of patients receiving mivacurium 250 µg/kg
Figure 3
The time course of SBP after administration of mivacurium.
***P < 0.05, 200 vs. 250 µg/kg
Figure 4
The time course of DBP after administration of mivacurium.
***P < 0.05, 200 vs. 250 µg/kg
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The TOF-Guard was used to evaluate the neuromuscular
response. Some studies have supported its use by finding
that acceleromyography compares closely with other
more sophisticated equipment [26,27], whereas clinical
trials using the TOF-Guard to measure neuromuscular
function have been increased. However, it is not yet ac-
cepted as a monitor of definitive studies of neuromuscu-
lar blocking agents in anesthesia probably because it
does not register the neuromuscular function in a contin-
uous fashion, and can generate "noise" in the measure-
ment of the effect [20]. Previously, we utilized it to
evaluate the pharmacodynamics of rocuronium [6,28].
When used for rocuronium, data acquisition every 5 min
in the recovery period was enough to model the recovery
phase. Because of a fast recovery after mivacurium ad-
ministration, data acquisition in the recovery phase was
now performed every minute and the effect was also suc-
cessfully modeled, and results agreed with those previ-
ously published in the literature. We therefore
considered that, if any, the noise generated by TOF-
Guard measurements did not affect data modeling nor
results and conclusions of the current study. Unfortu-
nately and despite its relative low cost, capacity to retain
data sets and its easy-to-use, TOF-Guard is worldwide no
longer commercially available. It is being replaced by the
manufacturer company with equivalent equipment
named the TOF-Watch series (written personal commu-
nication from Biometer International A/S, Odense, Den-
mark, 1999), unable to retain data and therefore require
to be connected into a computer.
Finally, we simultaneously registered T and T4/T1. It has
been proposed that the T4/T1 is more sensitive than
evaluation of any single twitch of the TOF response
[29,30], and does not need an established control. By
evaluating the T response, significantly faster OA times
were identified with mivacurium 250 µg/kg, while all the
T1/T4 were similar between the two groups. This contro-
versy deserves further investigation.
Conclusions
The maximal effect of mivacurium 250 µg/kg was pro-
duced one minute faster than 200 µg/kg. However, it
was associated to a significant cardiovascular response.
We therefore conclude that the higher dose does not of-
fer a satisfactory clinical advantage over the lower dose
in infants under general anesthesia with isoflurane.
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